MS: Busting the Myths
February 16, 2023 | Research
Issue 81 of the Neurology Research Review provides a special focus on Multiple Sclerosis.
Download Neurology_Research_Review_Issue_81 by Dr. Jennifer Pereira.
In this issue, a post hoc analysis of the ASCLEPIOS I and II trials supports the consideration of ofatumumab as a first line therapy in recently diagnosed treatment-naïve pwMS, the SWEDISH RIFUND-MS study provides evidence that rituximab (1000mg followed by 500mg every 6 months) is superior to dimethyl fumarate in preventing relapses in patients with early RRMS, and an analysis of the EXPAND extension trial supports the clinical utility of siponimod for long-term treatment of SPMS.